|
Completed
|
NCT05700344 -
SOGUG-AVELUMAB_RWD
|
|
|
Recruiting
|
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A |
|
Recruiting
|
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 |
|
Recruiting
|
NCT04953104 -
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression
|
Phase 2 |
|
Withdrawn
|
NCT06050954 -
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
|
Phase 2 |
|
Active, not recruiting
|
NCT03534804 -
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
|
Phase 2 |
|
Active, not recruiting
|
NCT00365157 -
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT04936230 -
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
|
Phase 2 |
|
Recruiting
|
NCT05544552 -
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
|
Phase 1/Phase 2 |
|
Active, not recruiting
|
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 |
|
Terminated
|
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
|
|
Terminated
|
NCT03115801 -
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
|
Phase 2 |
|
Active, not recruiting
|
NCT03854474 -
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
|
Phase 1/Phase 2 |
|
Terminated
|
NCT02693717 -
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
|
Phase 2 |
|
Recruiting
|
NCT04848519 -
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
|
Phase 2 |
|
Active, not recruiting
|
NCT04724018 -
Sacituzumab Govitecan Plus EV in Metastatic UC
|
Phase 1 |
|
Terminated
|
NCT04003610 -
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
|
Phase 2 |
|
Recruiting
|
NCT04383067 -
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
|
Phase 2 |
|
Not yet recruiting
|
NCT03108261 -
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
|
Phase 2 |
|
Recruiting
|
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 |